Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Cagrisema (2.5mg + 2.5mg)
Agonista dual de amilina/calcitonina estudiado para investigación de saciedad
Cagrisema (2.5mg + 2.5mg) is a research-grade compound in the glp-1 / weight management category. It is widely used in laboratory settings for investigating its effects on biological systems. Available from MiPeptidos in 1 sizes, every batch is HPLC-verified at ≥99% purity with a full Certificate of Analysis included.
- Dual-pathway appetite control
- Better than either alone
- Once-weekly dosing
- Over 20% weight loss potential
Research suggests appetite suppression starts within the first week and feels more complete than single-pathway peptides, since CagriSema engages both GLP-1 and amylin satiety circuits simultaneously. By weeks 4-8, studies report dramatic reductions in hunger, portion sizes, and food preoccupation. Phase 2 trials showed 17% weight loss at just 20 weeks — significantly more than either semaglutide or cagrilintide alone. Users frequently describe feeling genuinely indifferent to food rather than just less hungry.
$31.39/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Dual-Pathway Satiety.
16-week amylin + GLP-1 combination protocol — two pathways, one injection
CagriSema is a co-formulation of cagrilintide (a long-acting amylin receptor agonist) and semaglutide (a GLP-1 receptor agonist), both developed by Novo Nordisk. In Phase 2, this combination achieved 17.1% weight loss at just 20 weeks — significantly more than either component alone — by simultaneously engaging two distinct satiety pathways in the brain.
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. John Wilding
Professor of Medicine, University of Liverpool
Lead investigator for STEP 1 (semaglutide) and key advisor on CagriSema development. One of the world's most published obesity medicine researchers.
CagriSema represents the most logical pharmacological combination in obesity medicine — two distinct satiety pathways in a single injection. The Phase 2 data exceeded expectations.
The fixed-ratio combination simplifies dosing. Escalate per the semaglutide titration schedule. Monitor for GI tolerability — dual-pathway gastric slowing can intensify nausea during escalation.
Fuente: CagriSema Phase 2 commentary; Lancet obesity reviews
Dr. Lars Berthelsen
Senior Clinical Scientist, Novo Nordisk
Lead author of the CagriSema Phase 2 proof-of-concept study in Nature Medicine. Instrumental in designing the fixed-ratio combination approach.
Co-administration of cagrilintide and semaglutide produced significantly greater weight loss than either monotherapy, validating the dual amylin-GLP-1 mechanism hypothesis.
The 2.4mg cagrilintide + 2.4mg semaglutide combination represents the optimal ratio based on Phase 2 dose-finding. Lower doses still provide meaningful benefit for tolerability-limited patients.
Fuente: Enebo et al. (2021) Nature Medicine (PMID: 34349264)
Dr. Peter Attia
Physician, Founder of Attia Medical PC
MD from Stanford. Host of 'The Drive.' Author of 'Outlive: The Science and Art of Longevity.' Specialist in longevity and metabolic medicine.
CagriSema is one of the most interesting developments in metabolic pharmacology because it proves that engaging multiple satiety circuits is more powerful than maximizing a single one.
The combination approach reinforces that obesity requires multi-pathway intervention. Pair with high protein intake and resistance training. DEXA monitoring every 12 weeks.
Fuente: The Peter Attia Drive Podcast: GLP-1 and obesity discussions
Dr. Thomas Lutz
Professor of Veterinary Physiology, University of Zurich
World's leading expert on amylin physiology. Over 200 publications on amylin's role in appetite, glucose regulation, and energy homeostasis.
Amylin and GLP-1 act on different brainstem and hypothalamic nuclei. Combining them activates complementary circuits — area postrema for meal termination and arcuate nucleus for tonic suppression.
The biology predicts additive effects, and the clinical data confirms it. This is textbook rational drug combination — two mechanisms of action targeting the same disease through different pathways.
Fuente: J Endocrinology amylin reviews (PMID: 30307155); University of Zurich research
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Low starting dose for dual-receptor adaptation. Both amylin and GLP-1 pathways begin activating. GI side effects may be more pronounced than either monotherapy. Inject on the same day each week.
Follow semaglutide-equivalent titration schedule, increasing both components proportionally. If GI intolerance occurs, hold at current dose for an additional 4 weeks before escalating.
Target maintenance combination. Phase 2 showed continued weight loss trajectory at 20 weeks. Long-term maintenance intended — weight regain expected upon discontinuation.
Research-grade CagriSema combination: reconstitute the 5mg (2.5mg+2.5mg) vial with 1mL bacteriostatic water. The combination is pre-mixed at a 1:1 ratio. Calculate dose volume based on desired cagrilintide+semaglutide amount.
CagriSema is designed for continuous long-term use — not cycled. Weight regain is expected upon discontinuation based on both component drugs' withdrawal data. If stopping, taper gradually over 4-8 weeks.
Lyophilized: store at -20°C. Reconstituted: refrigerate at 2-8°C, use within 30 days. Protect from light. Both peptide components are stable when co-formulated in lyophilized form.
Single subcutaneous injection once weekly — the combination is designed as one injection, not two separate shots. Rotate sites weekly. Same day each week. Timing of day does not matter.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
Dual-Pathway Activation & Adaptation
- Both amylin (area postrema) and GLP-1 (hypothalamus) satiety pathways activating simultaneously
- Meal size reduction from amylin signaling + tonic appetite suppression from GLP-1
- GI adaptation — nausea may be more pronounced due to dual gastric emptying delay
- Glucose-dependent insulin secretion enhanced via GLP-1R activation
- Typical weight loss: 2-4% of body weight
Base de investigación: Enebo et al. (2021) Nature Medicine (PMID: 34349264)
Dose Escalation & Synergistic Weight Loss
- Progressive dose escalation engages both pathways more strongly
- Appetite reduction significantly greater than either monotherapy
- Post-meal satiety (amylin) + inter-meal hunger reduction (GLP-1) = comprehensive control
- GI side effects typically stabilize by week 8-10
- Typical weight loss: 8-12% of body weight
Base de investigación: CagriSema Phase 2 dose-escalation data (PMID: 34349264)
Target Dose & Peak Combined Effect
- Full dual-agonist effect at 2.4mg+2.4mg target dose
- Phase 2: 17.1% weight loss at 20 weeks — trajectory still declining
- Comprehensive metabolic improvement: glucose, lipids, blood pressure
- Both satiety circuits maximally engaged — patients report dramatic reduction in food preoccupation
- Typical weight loss: 14-17% of body weight
Base de investigación: Enebo et al. (2021) Nature Medicine (PMID: 34349264)
Long-Term Maintenance (Awaiting Phase 3 Data)
- Phase 3 REDEFINE program will provide 52-68 week data
- Weight loss trajectory had not plateaued at 20 weeks in Phase 2
- Extrapolation from component drugs suggests 20-25% weight loss possible at 52+ weeks
- Cardiovascular outcomes data expected from REDEFINE-4 trial
- Ongoing therapy required — discontinuation leads to weight regain
Base de investigación: REDEFINE Phase 3 program (ongoing); component drug long-term data
Mecanismo de Acción
3 vías biológicas distintas a través de las cuales opera este péptido.
Dual Amylin + GLP-1 Receptor Activation
Simultaneously engages amylin receptors (area postrema) and GLP-1 receptors (hypothalamus) — two anatomically and pharmacologically distinct satiety circuits in a single injection.
- Amylin pathway: area postrema → meal termination signals → reduced meal SIZE
- GLP-1 pathway: hypothalamus → tonic appetite suppression → reduced meal FREQUENCY and desire
- Distinct receptor types (calcitonin-R/RAMP vs GLP-1R) ensure no competitive binding
- Additive effects confirmed: CagriSema > cagrilintide + semaglutide alone
Enebo et al. (2021) Nature Medicine (PMID: 34349264); Lutz (2018)
Dual Gastric Emptying Delay
Both components independently slow gastric emptying through different mechanisms, producing more sustained post-meal satiety and glucose control.
- Amylin slows gastric emptying via vagal pathways from area postrema
- GLP-1 slows gastric emptying through direct GI tract receptor activation
- Combined delay enhances satiety duration after meals
- Primary driver of GI side effects during escalation — explains higher nausea rates
Amylin and GLP-1 gastric emptying literature; CagriSema Phase 2 AE data
Comprehensive Glucose Homeostasis
GLP-1 enhances glucose-dependent insulin secretion while amylin suppresses inappropriate postprandial glucagon, providing comprehensive glycemic control.
- GLP-1R activation on beta cells enhances insulin secretion (glucose-dependent)
- Amylin suppresses postprandial glucagon secretion from alpha cells
- Combined effect: reduced fasting glucose, reduced post-meal spikes
- Minimal hypoglycemia risk due to glucose-dependent mechanisms
Amylin and GLP-1 glucose physiology; pramlintide + exenatide combination studies
Investigación Publicada
4 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Safety and efficacy of combination of cagrilintide and semaglutide: a phase 2 trial
Enebo LB, Berthelsen KK, Kankam M, et al. — Nature Medicine (2021)
Hallazgo Clave: CagriSema achieved 17.1% weight loss at 20 weeks — significantly more than cagrilintide alone (9.4%) or semaglutide alone (8.0%). Validates the dual amylin+GLP-1 hypothesis.
Once-weekly cagrilintide for weight management in people with overweight and obesity
Lau DCW, Erichsen L, Francisco-Ziller N, et al. — The Lancet (2021)
Hallazgo Clave: Cagrilintide monotherapy: 10.8% weight loss at 4.5mg at 26 weeks. Establishes the amylin component's independent contribution to CagriSema.
Amylin as a future obesity treatment
Lutz TA, Coester B, Whiting L, et al. — Journal of Endocrinology (2018)
Hallazgo Clave: Foundational review: amylin acts through area postrema to reduce meal size via distinct neural circuits from GLP-1. Predicts additive benefit of amylin+GLP-1 combination — confirmed by CagriSema data.
STEP 1: Semaglutide 2.4mg for Weight Management
Wilding JPH, Batterham RL, et al. — New England Journal of Medicine (2021)
Hallazgo Clave: Semaglutide 2.4mg: 14.9% weight loss at 68 weeks as monotherapy. CagriSema exceeded this in just 20 weeks, demonstrating the value of adding amylin receptor agonism.
Potencia tu Protocolo de Investigación
3 SinergiasLa investigación sugiere combinar Cagrisema (2.5mg + 2.5mg) con estos péptidos para mecanismos complementarios.
Dual gastric emptying delay from both amylin and GLP-1 pathways makes GI protection especially important for CagriSema protocols.
Critical for tolerability during CagriSema escalation when dual-pathway GI effects are strongest. May reduce the GI-driven discontinuation rate.
With CagriSema potentially producing 20%+ weight loss, lean mass preservation through GH support becomes essential.
Counterbalances the lean mass loss that accompanies aggressive weight reduction. Resistance training + GH support is the recommended mitigation strategy.
MOTS-c enhances mitochondrial function and exercise capacity, supporting physical activity during CagriSema-induced caloric restriction.
Supports exercise capacity and metabolic rate when caloric intake is significantly reduced. Helps maintain physical activity levels needed for lean mass preservation.
Especificaciones
Precios
| Tamaño | Por Vial | Paquete de 10 |
|---|---|---|
5mg (2.5mg+2.5mg) | $70.00 | $595.00 |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Investigational combination — not approved for any use
CagriSema is in Phase 3 trials (REDEFINE program). Neither the combination nor cagrilintide alone has regulatory approval. Research peptide form carries additional quality uncertainty.
Thyroid C-cell tumors and pancreatitis (GLP-1 class warnings)
The semaglutide component carries GLP-1 class warnings including thyroid C-cell tumors in rodents and pancreatitis risk. CONTRAINDICATED with MTC or MEN 2 family history.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
Up to 50% OffSemaglutide
Estudiado clínicamente para una reducción de peso constante — una vez por semana
Up to 60% OffTirzepatide
El agonista dual más estudiado para la reducción de peso
Up to 42% OffRetatrutide
Agonista de triple receptor estudiado para una actividad metabólica mejorada
Up to 38% OffLiraglutide
GLP-1 diario estudiado para la regulación constante del apetito